LSL Pharma Group Engages Paradox as Investor Relations Services Provider
LSL Pharma Group Engages Paradox as Investor Relations Services Provider
LSL Pharma Group is a Canadian integrated pharmaceutical company specializing in the development, manufacturing and distribution of high-quality natural health products and dietary supplements in solid dosage forms, as well as high quality sterile ophthalmic pharmaceutical products. For more information, please visit and .BOUCHERVILLE, Québec, Oct. 06, 2023 (GLOBE NEWSWIRE) -- LSL Pharma Group Inc. (TSXV: LSL) – (the "Company" or "LSL Pharma Group"), a Canadian integrated pharmaceutical company, is pleased to announce that it has retained on October 5, 2023 the services of Paradox Public Relations Inc. ("Paradox") to provide investor relations services on behalf of the Company. Paradox is a Montréal-based investor relations consultancy firm that has been in business for over 20 years. Paradox will focus on developing and expanding the Company's communications and visibility with the investment community through a comprehensive investor relations program.
鮑切維爾，QuéBEC，2023年10月6日(環球通訊社)-LSL製藥集團有限公司(多倫多證券交易所股票代碼：LSL)-(The“The”)公司“或”LSL醫藥集團加拿大綜合製藥公司)高興地宣佈，它已於2023年10月5日保留了Paradox Public Relationship Inc.(悖論“)代表公司提供投資者關係服務。Paradox是一家總部位於Montréal的投資者關係諮詢公司，已有20多年的業務。Paradox將專注於通過全面的投資者關係計劃發展和擴大公司與投資界的溝通和知名度。
The Investor Relations Agreement has a term of 12 months and can be terminated at any time without charge by either party by giving 30 days' notice in writing. Paradox will be paid a monthly fee of $10,000, plus applicable taxes, and are granted stock options to acquire up to 300,000 Class A shares of the Company at a price of $0,70 per share, which options shall be for a period of 10 years and vest in four equal tranches, quarterly over a twelve (12) months period, the whole in accordance with the current stock option plan of the Company and Policy 3.4 of the TSXV. The Investor Relations Agreement as well as the professional engagement fees and granting of the stock options remains subject to TSX Venture Exchange approval.
投資者關係協定的有效期為12個月，任何一方均可隨時給予30天書面通知而不收取任何費用而終止。Paradox將獲得每月10,000美元的費用，外加適用的稅款，並被授予以每股0，70美元的價格收購最多300,000股本公司A類股票的股票期權，這些期權的期限為10年，分四個等量部分，在十二(12)個月期間按季度授予，全部根據本公司當前的股票期權計劃和TSXV的第3.4號政策。投資者關係協定以及專業聘用費和授予股票期權仍有待多倫多證券交易所創業板交易所的批准。
ABOUT LSL PHARMA GROUP INC.
約 LSL製藥 集團公司
LSL Pharma Group is a Canadian integrated pharmaceutical company specializing in the development, manufacturing and distribution of high-quality natural health products and dietary supplements in solid dosage forms, as well as high quality sterile ophthalmic pharmaceutical products. For more information, please visit and .
LSL Pharma Group是一家加拿大綜合性製藥公司，專門開發、製造和分銷高質量的天然保健品和固體劑型的膳食補充劑，以及高質量的無菌眼科藥品。有關更多資訊，請訪問和。
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
都不是這個多倫多證券交易所 風險投資 交易所 也不是 它的 監管 服務 提供商 (作為 那 術語 是 已定義 在……裡面 中國的政策 這個 多倫多證券交易所風險投資公司 交易所) 承擔責任 為 充分性或 精確度 的 這放手。
CONTACT:
François Roberge, President and Chief Executive Officer
Telephone: 514-664-7700
Email: Investors@groupelslpharma.com
聯繫方式：
FrçOis Roberge、總裁和首席執行官
電話：514-664-7700
電子郵件：Investors@groupelslpharma.com
